Literature DB >> 11778052

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.

Yohei Maeshima1, Akulapalli Sudhakar, Julie C Lively, Kohjiro Ueki, Surender Kharbanda, C Ronald Kahn, Nahum Sonenberg, Richard O Hynes, Raghu Kalluri.   

Abstract

Tumstatin is a 28-kilodalton fragment of type IV collagen that displays both anti-angiogenic and proapoptotic activity. Here we show that tumstatin functions as an endothelial cell-specific inhibitor of protein synthesis. Through a requisite interaction with alphaVbeta3 integrin, tumstatin inhibits activation of focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3-kinase), protein kinase B (PKB/Akt), and mammalian target of rapamycin (mTOR), and it prevents the dissociation of eukaryotic initiation factor 4E protein (eIF4E) from 4E-binding protein 1. These results establish a role for integrins in mediating cell-specific inhibition of cap-dependent protein synthesis and suggest a potential mechanism for tumstatin's selective effects on endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11778052     DOI: 10.1126/science.1065298

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  104 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

2.  NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele.

Authors:  Hiroyasu Tsukaguchi; Akulapalli Sudhakar; Tu Cam Le; Trang Nguyen; Jun Yao; Joshua A Schwimmer; Asher D Schachter; Esteban Poch; Patricia F Abreu; Gerald B Appel; Aparecido B Pereira; Raghu Kalluri; Martin R Pollak
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.

Authors:  Ming Yi; Takao Sakai; Reinhard Fassler; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

Review 4.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

5.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.

Authors:  Akulapalli Sudhakar; Pia Nyberg; Venkateshwar G Keshamouni; Arjuna P Mannam; Jian Li; Hikaru Sugimoto; Dominic Cosgrove; Raghu Kalluri
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

Review 6.  Endothelial FAK as a therapeutic target in disease.

Authors:  Giovanni A Infusino; Jeffrey R Jacobson
Journal:  Microvasc Res       Date:  2011-10-06       Impact factor: 3.514

7.  The role of type IV collagen and basement membranes in cancer progression and metastasis.

Authors:  Harikrishna Tanjore; Raghu Kalluri
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

Review 8.  Pivotal role for decorin in angiogenesis.

Authors:  Hannu Järveläinen; Annele Sainio; Thomas N Wight
Journal:  Matrix Biol       Date:  2015-02-07       Impact factor: 11.583

9.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.

Authors:  Hans Petter Eikesdal; Hikaru Sugimoto; Gabriel Birrane; Yohei Maeshima; Vesselina G Cooke; Mark Kieran; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.